Theolytics Expands Oxford R&D Site, Adding Space for Clinical Development of Oncolytic Virus Therapy THEO-260
The University of Oxford spinout has moved into a new 5,500-square-foot facility as it prepares to advance its ovarian cancer candidate and follow-on solid tumor programs; however, the publicly available evidence remains primarily preclinical, and efficacy in humans has yet to be determined in trials.